Participant profile: Reset Therapeutics
Using a platform directed toward molecular targets
across the therapeutic spectrum.
Reset Therapeutics is an integrated discovery and development company with a therapeutic platform that can be directed toward molecular targets across the therapeutic spectrum. The company’s mission is to discover and develop new drugs to treat human disease by restoring normal circadian clock function.
Enter your email address to follow The Hive and get the latest updates on participants and milestones – followed by the email address submission box.
Designing therapeutics that treat disease by restoring the body’s natural circadian rhythms
Reset is pioneering first-in-class approaches to treating diseases by restoring the body’s natural 24-hour, or circadian, rhythms. More than half of the best-selling drugs in the US and more than 100 of the WHO essential medicines target rhythmic proteins, but Reset is the first company built exclusively to design clock-modifying therapeutics.
Circadian rhythms can influence sleep-wake cycles, hormone release, body temperature, and other important bodily functions. Chronic disruption of molecular clocks contributes to disease, while a variety of lifestyles/behaviors and chronic disease states disrupt circadian function. These disruptions disconnect physiological needs from environmental cues. Adverse changes in hormonal, behavioral and cellular rhythms are hallmarks of cardiometabolic, CNS and inflammatory disorders, some cancers, and senescence.
Reset’s most advanced drug discovery programs target orphan metabolic and CNS disorders, the latter in partnership with Alkermes. Reset is also pursuing novel therapies to address excessive daytime sleepiness in Parkinson’s disease with funding from The Michael J. Fox Foundation.
Combining the expertise of leaders in science and business
Reset was co-founded by leaders in the field of circadian biology and Bay City Capital. The company is comprised of a highly skilled and educated team of scientists, inventors, entrepreneurs, and visionaries.
Meet the team
Ross Bersot, CFA
President and CEO
Ross founded Reset Therapeutics in 2008 with Dr. Ronald Evans of the Salk Institute and Drs. Joseph Takahashi and Masashi Yanagisawa from the University of Texas Southwestern Medical Center. Prior to co-founding Reset, Mr. Bersot served as a Managing Director of Bay City Capital, where he focused on investment opportunities in visionary biopharmaceutical and technology companies.
We hope to bring breakthrough treatments to patients in need. Access to the Elsevier Solutions will inform our decision-making process, and hopefully, our chances of developing safe and effective new drugs.
Paul Humphries, Ph.D.
Head of Drug Discovery
Paul joined Reset Therapeutics as the Head of Drug Discovery at Reset Therapeutics after serving as a Senior Principal Scientist at Pfizer. where he worked in the area of Metabolic Diseases.
Given the fact that Reset is a phenotypic, disease-area agnostic research company it is important to have access to all of the top scientific journals offered by ScienceDirect. In my previous life as chemist I also enjoyed using Reaxys and it’s great to have access to this excellent resource once again. Going forward, I look forward to utilizing Pathway Studio in order to better mine information related to our current mechanisms of action.
Jamie Cope, Ph.D.
Director, Translational Medicine
Jamie is responsible for coordinating the process of moving Reset’s lead Cryptochrome modulator program from proof of concept to IND submission and early to mid-stage clinical development.
Since having had the opportunity of using Elsevier’s Hive, I can already appreciate the convenience and power of a coordinated set of tools built on Elsevier’s growing dominance. To offer one concrete example, some years ago I spent more time and more emails than I care to admit in the ultimately unsuccessful search for a 1970’s era monograph on a grandfathered therapeutic polymer. In less than five minutes on PharmaPendium in The Hive, I found it.
Senior Principal Scientist
Tod is currently the biology lead for the orexin program for the treatment of narcolepsy. He made the initial discovery of orexin receptor allosteric modulators at Reset as part of an NIH-funded grant for narcolepsy and he continues to further characterize these molecules.
The immediate access to top scientific journals offered by ScienceDirect is important in maintaining pace for a nimble and cutting-edge research organization.
Melissa is a medicinal chemist with 13 years of experience in the pharmaceutical industry. Before joining Reset Therapeutics, she worked at Gilead, Theravance and MyoKardia, where she contributed to bioactive molecules synthesis and design for treating diseases affecting the liver, heart, lung and intestine.
I used Reaxys to help us design synthetic route more efficiently. I see a great benefit for early-stage companies to partake in The Hive and have access to Pathway Studio, Embase, PharmaPendium, Reaxys, and ScienceDirect. The Hive will definitely help with R&D productivity, efficiency and organization.
The Hive provides a coordinated set of tools to empower the Reset team’s research
"Given the fact that Reset is a phenotypic, disease-area agnostic research company, it is important to have access to all of the top scientific journals offered by ScienceDirect. In my previous life as chemist, I also enjoyed using Reaxys and it’s great to have access to this excellent resource once again. Going forward, I look forward to utilizing Pathway Studio in order to better mine information related to our current mechanisms of action." Paul Humphries, PhD, Head of Drug Discovery
"As of now, I used Reaxys to help us design synthetic route more efficiently. I see a great benefit for early-stage companies to partake in The Hive and have access to Pathway Studio, Embase, PharmaPendium, Reaxys, and ScienceDirect. The Hive will definitely help with R&D productivity, efficiency and organization." Melissa Fleury, Scientist
"The immediate access to top scientific journals offered by ScienceDirect is important in maintaining pace for a nimble and cutting-edge research organization." Tod Steinfeld, Senior Principal Scientist
Videos and media
Learn more about Elsevier's R&D solutions for drug discovery
and development utilized by Reset Therapeutics:
Improve R&D productivity with a chemistry research solution that delivers experimental facts on chemical structures, properties, reactions and procedures.
Learn more about Reaxys
Reaxys Medicinal Chemistry
Empower hit identification and lead optimization with normalized compound–target affinity data and comprehensive pharmacokinetic, efficacy, toxicity, safety and metabolic profiles.
Learn more about Reaxys Medicinal Chemistry
Increase the discovery of biomedical evidence to support critical life sciences functions, with access to the world's most comprehensive biomedical literature database.
Learn more about Embase
Enable better informed preclinical drug safety decisions with comprehensive, fully searchable FDA/EMA drug approval documents and comparative extracted drug safety data.
Learn more about PharmaPendium
Enable researchers to more effectively and efficiently search authoritative, full-text scientific, technical and health content through the use of smart, intuitive functionality.
Learn more about ScienceDirect
Enable better understanding of biological processes underlying disease progression and treatment response, with a solution that helps researchers interpret experimental data from scientific literature.
Learn more about Pathway Studio
Help researchers discover trends, partners and experts with the world’s largest abstract & citation database of peer-reviewed literature, including tools to track, analyze and visualize research.
Learn more about Scopus